Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee

Apr-20

AUTHORS : Robert Flynn, Pharmacovigilance and Epidemiology Department, European Medicines Agency, Domenico Scarlattilaan 6, 1083 HN Amsterdam, Netherlands AND Medicines Monitoring Unit (MEMO), Division of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital, Dundee DD1 9SY – Email: robert.flynn@ema.europa.eu / r.w.v.flynn@dundee.ac.uk – Profile: https://discovery.dundee.ac.uk/en/persons/robert-flynn

JOURNAL : Clinical Pharmacology and Therapeutics

REFERENCE: 107(4):957-965

DOI : 10.1002/cpt.1775

Ability of Primary Care Health Databases to Assess Medicinal Products Discussed by the European Union Pharmacovigilance Risk Assessment Committee

More publications

Characteristics, risk factors and clinical impact of penicillin and other antibiotic allergies in adults in the UK General Practice: a population-based cohort study

Glucose Lowering through Weight management (GLoW): a randomised controlled trial of the clinical and cost effectiveness of a diabetes education and behavioural weight management programme vs a diabetes education programme in adults with a recent diagnosis of type 2 diabetes

Characteristics and Outcomes of Over a Million Patients with Infammatory Bowel Disease in Seven Countries: Multinational Cohort Study and Open Data Resource